Skip to main content
Midas Edge

Sagimet Biosciences Inc.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

SGMT$10.83+9.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Stockholders’ Equity

STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​
​ · ​ · Series A · ​ · Series B · ​ · Additional · ​ · ​ · ​ · ​ · Other · ​ · Total
​ · ​ · Common Stock · ​ · Common Stock · ​ · Paid-in · ​ · Accumulated · ​ · Comprehensive · ​ · Stockholders’
​ · Shares · Amount · Shares · Amount · Capital · Deficit · Income · Equity
Balance at January 1, 2024​21,375,402​$2​1,520,490​$—​$340,777​$(249,744)​$30​$91,065
Sale of Series A common stock, net of issuance costs of $7,796​9,000,000​​1​—​​—​​104,704​​—​​—​​104,705
Issuance of Series A common stock upon exercise of stock options17,995​​—​—​​—​​114​​—​​—​​114
Issuance of Series A common stock for vesting of restricted stock units​281,458​​—​—​​—​​—​​—​​—​​—
Stock-based compensation expense​—​​—​—​​—​5,288​—​—​5,288
Unrealized gain on marketable securities—​​—​—​​—​—​—​200​200
Net loss—​​—​—​​—​—​(45,567)​—​(45,567)
Balance at December 31, 202430,674,855​$3​1,520,490​$—​$450,883​$(295,311)​$230​$155,805
Issuance of Series A common stock for vesting of restricted stock units​281,462​​—​—​​—​​—​​—​​—​​—
Issuance of Series A common stock upon exercise of stock options​44,792​​—​—​​—​​275​​—​​—​​275
Conversion of Series B common stock to Series A common stock​952,996​​—​(952,996)​​—​​—​​—​​—​​—
Stock-based compensation expense—​​—​—​​—​6,449​—​—​6,449
Unrealized loss on marketable securities—​​—​—​​—​—​—​(110)​(110)
Net loss—​​—​—​​—​—​(51,038)​—​(51,038)
Balance at December 31, 202531,954,105​$3​567,494​$—​$457,607​$(346,349)​$120​$111,381

SAGIMET BIOSCIENCES INC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.